Not applicableStudy completedNCT03896984
What this trial is testing
Descriptive Analysis of Clinical Outcomes in Patients With Prostate Gland Cancer, Which Spreads to Other Parts of the Body, Who Were Treated First With Novel Anti-hormone Therapy Followed by a Second Line Treatment With Novel Anti-Hormone Therapy or RadIum-223 (Xofigo).
Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Bayer 346